Navigation Links
HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Date:11/5/2007

ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced the final results of a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. This Phase 2b study demonstrated that, with half as many injections as Pegasys (peginterferon alfa 2a), Albuferon was just as effective in achieving sustained virologic response (SVR) an undetectable amount of virus in the blood at 24 weeks following the end of treatment with comparable safety and less impairment of health-related quality of life on treatment. Albuferon is administered every two weeks, while peginterferon alfa-2a requires administration every week.

The final Phase 2b data are being presented this week at the 58 th AASLD Annual Meeting in Boston. In two additional press releases also issued by HGS today, the Company announced the full presentations at AASLD of quality-of-life data from the Phase 2b trial, and results from the Phase 2 trial of Albuferon in combination with ribavirin in patients with chronic hepatitis C who had not responded to previous interferon-based treatment regimens.

The final Phase 2b results suggest that the every-two-week dosing regimen of Albuferon halves the number of injections that are required with peginterferon alfa-2a, while providing at least comparable efficacy, comparable safety and the potential for less impairment of quality of life and daily activity, said Stefan Zeuzem, M.D., Professor of Medicine and Chief, Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany. We are continuing the evaluation of the 900-mcg and 1200-mcg doses of Albuferon in larger populations in Phase 3 trials. We also conclude that monthly dosing of Albuferon deserves further evaluation.

In the open-label, multi-center, active-controlled Phase 2b trial, 458 treatment-naive patients with
'/>"/>

Contact: Jerry Parrott
301-315-2777
Edelman Public Relations
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... neutrality during wakefulness and is restored during sleep, suggests ... 9, 2010, in San Antonio, Texas, at SLEEP 2010, ... Societies LLC. Results indicate that prior wakefulness caused ... slightly but significantly greenish tint. Overnight sleep restored ...
... satisfaction is related to the amount of sleep they ... research abstract that will be presented Wednesday, June 9, ... 24th annual meeting of the Associated Professional Sleep Societies ... new parents was strongly associated with objective total sleep ...
... rate of disease progression in a clinical trial of ... Hopkins, Roswell Park Cancer Institute and Duke University. ... blood supply to prostate tumors by blocking new blood ... blood vessels to supply nutrients. The multicenter trial ...
... Stress-reducing psychological intervention helps to increase survival and ... cancer over the long-term, according to results of ... Cancer Research , a journal of the American ... intervention arm evidenced significant emotional improvement and more ...
... quality of human life ― especially embryonic stem cells, which ... However, basic scientific problems still remain unresolved but Tel ... "In order to use embryonic stem cells as ... strategies to control their differentiation so we get exactly the ...
... Drug Administration,s abilities to discover potential threats to food ... by impediments to efficient use of its limited resources ... on risks, says a new report by the Institute ... more proactively tackle food safety problems, FDA should implement ...
Cached Medicine News:Health News:Sleep colors your view of the world: Study suggests sleep may restore color perception 2Health News:First-time parents' daily sleep duration predicts their relationship satisfaction 2Health News:Drug that restricts blood supply to prostate tumors delays disease progression 2Health News:Psychological intervention provides enduring health benefits for women with breast cancer 2Health News:A launchpad for stem cell research 2Health News:FDA should adopt risk-based approach to food safety 2Health News:FDA should adopt risk-based approach to food safety 3
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Soft white rubber tube with Murphy eye. ... tube. Two high volume cuffs (One inside other) ... is designed to allow maximum access and optimum ... ventilation. The tube shaft has a special laser-guard ...
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. S...
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. St...
... For Rapid Medication Delivery., ,Designed ... cuffed tube incorporates an additional lumen ... delivery below the cuff., ,SHERIDAN ... allow for CO2 monitoring, pressure monitoring ...
Medicine Products: